Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

BioTime lays groundwork for Japanese licensing of Hextend

Jan. 20, 1998

Filgrastim reduces neutropenia and morbidity associated with AML treatment

Jan. 20, 1998

Raloxifene launched in U.S.

Jan. 19, 1998

Lilly reports new benzothiophenes for gynecological and other disorders

Jan. 19, 1998

Merck subsidiary and Autogen collaborate on obesity research

Jan. 19, 1998

Takeda discloses compounds for cachexia

Jan. 16, 1998

IP-10 available for licensing from NIH

Jan. 16, 1998

Japanese marketing agreement announced for Bio-Technology General's hGH

Jan. 15, 1998

Abbott in-licenses lipid-lowering drug from Fournier

Jan. 14, 1998

IC-351 advances to phase II for MED

Jan. 14, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...